Mumbai: Sales of Mounjaro (tirzepatide), Eli Lilly‘s blockbuster weight-loss and diabetes drug, jumped nearly nine times since its launch in March to ₹26 crore in June, a month that also saw the launch of Wegovy from competitor Novo Nordisk. In the last one month itself, Mounjaro sale doubled from ₹13 crore in May, according to data from PharmaTrac. So far the total sales value of Mounjaro is ₹50 crore in India.
In volume terms, the numbers over seven times since March to 88,000 units sold in June. In the last two months, the quantity of Mounjaro sold has grown threefold from 28,000 units in April, the data showed. On the other hand, a week within its launch, Wegovy that is available in self-injectable pen-filled version, recorded a sale of ₹2.53 crore, shows the data.
Doctors said the increased awareness as well as social media conversations and publicity about both the molecules is prompting many young adults in their thirties and early forties showing interest.
